stella

Lp(a)

June 2026 Research Brief

Read our full Lp(a) guide →

Active sponsors

Trials

DiagnosticsPh 3
Lepodisiran reduces arterial plaque in adults with high Lp(a) who have had heart events or are at high risk.

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

Eli Lilly and CompanyPosted: May 2026NCT07613294
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) orLillyTrials@Lilly.com
Drug / interventionPh 2
SYH2068 injection lowers lipoprotein(a) levels in adults with elevated Lp(a).

A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Posted: Jun 2026NCT07640217
Clinical Trials Information Group officerctr-contact@cspc.cn
Drug / interventionPh 3
Pelacarsen lowers lipoprotein(a) and reduces plaque in heart attack patients with elevated Lp(a).

Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL

Novartis PharmaceuticalsPosted: Jun 2026NCT07625306
Novartis Pharmaceuticalsnovartis.email@novartis.com
Drug / interventionPh 1
New formulation of inclisiran with polysorbate 80 compared to current formulation in healthy subjects.

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation

Novartis PharmaceuticalsPosted: Jun 2026NCT07626281
Novartis Pharmaceuticalsnovartis.email@novartis.com
Drug / interventionPh 1
Clazakizumab pharmacokinetics evaluated in Chinese patients with end-stage kidney disease on dialysis.

A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

CSL BehringPosted: Jun 2026NCT07619820
Trial Registration Coordinatorclinicaltrials@cslbehring.com
Drug / interventionPh 3
Laroprovstat/rosuvastatin combination reduces LDL cholesterol in treatment-naïve patients with high cholesterol.

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

AstraZenecaPosted: Jun 2026NCT07619131
AstraZeneca Clinical Study Information Centerinformation.center@astrazeneca.com
Drug / interventionPh 3
Laroprovstat/rosuvastatin combination reduces LDL cholesterol in patients with high cholesterol and heart disease.

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

AstraZenecaPosted: Jun 2026NCT07619118
AstraZeneca Clinical Study Information Centerinformation.center@astrazeneca.com
Drug / interventionPh 2
MK-7262 combined with enlicitide lowers lipoprotein(a) and LDL cholesterol in people with high Lp(a).

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Merck Sharp & Dohme LLCPosted: May 2026NCT07614984
Drug / interventionPh 1
Laroprovstat and AZD4954 interaction study measures how these drugs affect each other in healthy adults.

A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults

AstraZenecaEst. completion: Jul 2026NCT07513571
AstraZeneca Clinical Study Information Centerinformation.center@astrazeneca.com
Drug / interventionPh 1
VERVE-102 gene-editing therapy lowers cholesterol in patients with familial hypercholesterolemia or early heart disease.

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Verve Therapeutics, Inc.Est. completion: Aug 2026NCT06164730

Showing trials with activity in the past 30 days. See the full Lp(a) research landscape →

Condition guide

Lp(a) — the full picture

Research landscape, trial types, and what eligibility typically looks like — written for patients but useful for everyone.

Read the condition guide →

Monthly digest

Get this brief every month

We’ll email you the Lp(a)brief as soon as it’s published — no login required.

Coming soon